When Hims & Hers launches its new weight-loss program, the digital-health company won't be joining in on the Ozempic craze, its CEO, Andrew Dudum, said.
While pricey drugs like Ozempic and Wegovy have exploded in popularity this year for their potential to help people lose weight, Hims & Hers plans to offer cheaper generic medications for weight loss, at least initially.
Ro's weight-loss program was fueling fast growth for the startup this year, but some patients struggled with insurance denials and delays in communication with Ro.
Dudum said during the company's third-quarter earnings call that Hims & Hers expected weight management to be "an extraordinarily valuable category."
Next year, in addition to launching its weight-loss program, the company plans to expand its new AI engine, which it's been beta testing in its psychiatry patients.
Persons:
Andrew Dudum, Dudum, It's
Organizations:
Business